SF3B1 and prostate carcinoma: Additionally, we have recently found that SF3B1 is overexpressed and associated with malignant features in prostate cancer [30] and hepatocellular carcinoma [42], supporting that SF3B1 could represent a valuable therapeutic target in cancer.